MARKET

ATRC

ATRC

Atricure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.34
-2.04
-4.70%
Closed 16:47 05/24 EDT
OPEN
43.03
PREV CLOSE
43.38
HIGH
43.71
LOW
41.11
VOLUME
235.41K
TURNOVER
--
52 WEEK HIGH
89.18
52 WEEK LOW
38.64
MARKET CAP
1.91B
P/E (TTM)
37.28
1D
5D
1M
3M
1Y
5Y
Insider Sell: Atricure
MT Newswires · 05/17 12:35
Local stocks slammed as stock market gets pummeled
The stock market got hammered on Cinco de Mayo and Greater Cincinnati stocks didn’t avoid the pain. The market plummeted more than 3% as of midday in the wake of the biggest Federal Reserve interest rate hike in more than two decades Wednesday afternoon. ...
American City Business Journals · 05/05 16:45
AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged.
Benzinga · 05/04 19:39
4 Analysts Have This to Say About AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the ...
Benzinga · 05/04 13:18
--SVB Leerink Adjusts AtriCure's Price Target to $75 from $95, Keeps Outperform Rating
MT Newswires · 05/04 09:55
--Needham Adjusts AtriCure's Price Target to $67 From $79 on Peer Multiple Compression, Reiterates Buy Rating
MT Newswires · 05/04 06:31
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:15
AtriCure: Q1 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by 3.13%, reporting an EPS of $-0.33 versus an estimate of $...
Benzinga · 05/03 21:12
More
No Data
Learn about the latest financial forecast of ATRC. Analyze the recent business situations of Atricure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
37.50%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATRC stock price target is 80.67 with a high estimate of 94.00 and a low estimate of 67.00.
High94.00
Average80.67
Low67.00
Current 41.34
EPS
Actual
Estimate
0.240.841.442.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 290
Institutional Holdings: 51.36M
% Owned: 110.96%
Shares Outstanding: 46.29M
TypeInstitutionsShares
Increased
73
2.04M
New
28
433.31K
Decreased
83
2.18M
Sold Out
24
251.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.88%
Healthcare Equipment & Supplies
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
B. Kristine Johnson
President/Chief Executive Officer/Director
Michael Carrel
Chief Financial Officer
Angela Wirick
Chief Operating Officer
Douglas Seith
Chief Human Resource Officer
Tonya Austin
Chief Technology Officer
Salvatore Privitera
Chief Marketing Officer
Justin Noznesky
Chief Scientific Officer
Vinayak Doraiswamy
Chief Compliance Officer
Karl Dahlquist
Independent Director
Mark Collar
Independent Director
Daniel Florin
Independent Director
Regina Groves
Independent Director
Karen Prange
Independent Director
Deborah Telman
Independent Director
Sven Wehrwein
Independent Director
Robert White
Independent Director
Maggie Yuen
No Data
No Data
About ATRC
AtriCure, Inc. is a provider of technologies for the treatment of atrial fibrillation (Afib) and related conditions. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage, and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers globally. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation includes Isolator Synergy Clamp and Multifunctional Pens and Linear Ablation Devices. Its Product for open ablation are cryoICE Cryoablation System. Its product for minimally invasive ablation are EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management includes AtriClip System and LARIAT System.

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.